German study tracks advanced cancer Drug's Real-Life impact
NCT ID NCT06619275
Summary
This study observed 10 patients in Germany with advanced gastrointestinal stromal tumors (GIST) who were already taking the drug ripretinib as part of their regular care. The goal was to collect real-world information on how the treatment affects patients' quality of life, how long it controls the cancer, and its safety outside of a controlled clinical trial. Researchers tracked patients' well-being and disease progression to better understand the drug's performance in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis für interdisziplinäre Onkologie und Hämatologie
Freiburg im Breisgau, Germany
Conditions
Explore the condition pages connected to this study.